Salmeterol-Fluticasone : The Role Revisited
© Journal of the Association of Physicians of India 2011..
Apart from the individual diseases, some patients also show overlapping manifestations of asthma and COPD. Nevertheless, the diagnosis of COPD is often delayed due to inaccessibility to spirometry; the prevalence of the asthma COPD overlap phenotype is rather high given the exposure to biomass smoke. Furthermore, the rates of exacerbations are twice as high compared to the patients with either of the diseases. A treatment strategy that would reduce the risk of exacerbations would contribute immensely to the management of such patients. Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatment with a combination of inhaled corticosteroids (ICS)/ long-acting β-agonists (LABA); several studies have shown improvement in the airflow limitation and reduction in the rate of exacerbations with salmeterol-fluticasone combination (SFC). Considering the association of COPD and cardiovascular diseases (CVD), it is critical to determine the cardiovascular safety of the LABA in such patients. Salmeterol is a highly selective partial b-2 agonist; the TORCH study and the studies comparing formoterol and salmeterol infer that there is no increased risk of new cardiovascular adverse events either with Salmeterol or SFC. Furthermore, the combination may provide certain degree of cardio-protection. Since COPD per se increases the risk of CVD, the cardio-safety of salmeterol outweighs its onset of action. SFC has well substantiated benefits in patients with asthma, COPD and high-risk patients such as those with an overlap of COPD and asthma symptoms, patients with elevated eosinophils and pre-existing CVD. An advisory board was hence conducted, which discussed the role of combination of salmeterol and fluticasone (SFC) not only in asthma and COPD but also in asthma COPD overlap phenotype. Based on the panel's clinical experience and the expertise derived thereof, the propositions regarding the place of SFC therapy in patients with stable and uncontrolled asthma, asthma COPD overlap phenotype and COPD has been put forth.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
The Journal of the Association of Physicians of India - 69(2022), 12 vom: 21. Dez., Seite 11-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vora, Agam [VerfasserIn] |
|---|
| Themen: |
6EW8Q962A5 |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM335922414 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335922414 | ||
| 003 | DE-627 | ||
| 005 | 20231225230946.0 | ||
| 007 | tu | ||
| 008 | 231225s2022 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335922414 | ||
| 035 | |a (NLM)35057598 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vora, Agam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salmeterol-Fluticasone |b The Role Revisited |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Journal of the Association of Physicians of India 2011. | ||
| 520 | |a Apart from the individual diseases, some patients also show overlapping manifestations of asthma and COPD. Nevertheless, the diagnosis of COPD is often delayed due to inaccessibility to spirometry; the prevalence of the asthma COPD overlap phenotype is rather high given the exposure to biomass smoke. Furthermore, the rates of exacerbations are twice as high compared to the patients with either of the diseases. A treatment strategy that would reduce the risk of exacerbations would contribute immensely to the management of such patients. Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatment with a combination of inhaled corticosteroids (ICS)/ long-acting β-agonists (LABA); several studies have shown improvement in the airflow limitation and reduction in the rate of exacerbations with salmeterol-fluticasone combination (SFC). Considering the association of COPD and cardiovascular diseases (CVD), it is critical to determine the cardiovascular safety of the LABA in such patients. Salmeterol is a highly selective partial b-2 agonist; the TORCH study and the studies comparing formoterol and salmeterol infer that there is no increased risk of new cardiovascular adverse events either with Salmeterol or SFC. Furthermore, the combination may provide certain degree of cardio-protection. Since COPD per se increases the risk of CVD, the cardio-safety of salmeterol outweighs its onset of action. SFC has well substantiated benefits in patients with asthma, COPD and high-risk patients such as those with an overlap of COPD and asthma symptoms, patients with elevated eosinophils and pre-existing CVD. An advisory board was hence conducted, which discussed the role of combination of salmeterol and fluticasone (SFC) not only in asthma and COPD but also in asthma COPD overlap phenotype. Based on the panel's clinical experience and the expertise derived thereof, the propositions regarding the place of SFC therapy in patients with stable and uncontrolled asthma, asthma COPD overlap phenotype and COPD has been put forth | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Fluticasone-Salmeterol Drug Combination |2 NLM | |
| 650 | 7 | |a Salmeterol Xinafoate |2 NLM | |
| 650 | 7 | |a 6EW8Q962A5 |2 NLM | |
| 650 | 7 | |a Fluticasone |2 NLM | |
| 650 | 7 | |a CUT2W21N7U |2 NLM | |
| 700 | 1 | |a Dhar, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Lancelot |e verfasserin |4 aut | |
| 700 | 1 | |a Koul, Parvaiz |e verfasserin |4 aut | |
| 700 | 1 | |a Gaonkar, Pratyusha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of the Association of Physicians of India |d 1961 |g 69(2022), 12 vom: 21. Dez., Seite 11-12 |w (DE-627)NLM000004707 |x 0004-5772 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2022 |g number:12 |g day:21 |g month:12 |g pages:11-12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2022 |e 12 |b 21 |c 12 |h 11-12 | ||